Your SlideShare is downloading. ×
Pharma point prophylactic human papillomavirus vaccines   canada drug forecast and market analysis to 2022
Pharma point prophylactic human papillomavirus vaccines   canada drug forecast and market analysis to 2022
Pharma point prophylactic human papillomavirus vaccines   canada drug forecast and market analysis to 2022
Pharma point prophylactic human papillomavirus vaccines   canada drug forecast and market analysis to 2022
Pharma point prophylactic human papillomavirus vaccines   canada drug forecast and market analysis to 2022
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Pharma point prophylactic human papillomavirus vaccines canada drug forecast and market analysis to 2022

1

Published on

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast and Market Analysis to 2022 Published: Mar 2014 Single User PDF: US$ 4995 Corporate User PDF: US$ 14985 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. 1© ReportsnReports.com / Contact sales@reportsandreports.com
  • 2. PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast and Market Analysis to 2022 The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector. Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. 2© ReportsnReports.com / Contact sales@reportsandreports.com
  • 3. PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast and Market Analysis to 2022 The anticipated addition of boys to routine HPV vaccine recommendations by different Canadian provinces is expected to serve as a significant driver to growth within the HPV vaccines market in Canada over the forecast period. In addition, from primary research insight, GlobalData projects Merck's nine-valent vaccine V503 to be widely adopted in the country. This will also significantly enhance the size of the HPV vaccines sector in Canada. Request a sample of this report @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=291521 . Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. 3© ReportsnReports.com / Contact sales@reportsandreports.com
  • 4. PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast and Market Analysis to 2022 Scope Overview of Prophylactic Human Papillomavirus Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in the Canada including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in the Canada from 2012-2022. Analysis of the impact of key events as well the drivers and restraints affecting the Canada Prophylactic Human Papillomavirus Vaccines disease market. Complete report is available @ http://www.reportsnreports.com/reports/291521- pharmapoint-prophylactic-human-papillomavirus-vaccines-canada-drug-forecast-and- market-analysis-to-2022.html . Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. 4© ReportsnReports.com / Contact sales@reportsandreports.com
  • 5. PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast and Market Analysis to 2022 Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Prophylactic Human Papillomavirus Vaccines Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales forecast for drugs from 2012-2022 in the Canada Buy a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=291521 . Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. 5© ReportsnReports.com / Contact sales@reportsandreports.com

×